Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma)
重组抗人DR5单克隆抗体（深圳龙瑞药业）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameRecombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Tongwei Shidai Shengwu Jishu Youxian GongsiLonn Ryonn Pharma Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesBeijing Xiantong International Technology Co Ltd
Inactive CompaniesBeijing Tongwei Shidai Shengwu Jishu Youxian GongsiLonn Ryonn Pharma Ltd
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A